June, 1st 2018

EB8018, a novel FimH blocker is well tolerated in a randomized, double-blind, placebo-controlled Phase I study in healthy volunteers

EB8018 is a novel, first-in-class oral small molecule that is a minimally absorbed, gut restricted molecule that represents a non-biologic, non-steroidal, non-immunomodulatory approach for the treatment of Crohn’s Disease.  EB8018 inhibits adhesion of FimH expressed by some pro-inflammatory bacteria such as Adherent, Invasive E Coli and Klebsiella to mannosylated receptors in the gut wall, thereby reducing the generation of inflammatory cytokines.

download the abstract


May 29th, 2018


© 2016-2018 Enterome & INRA


MSPminer reconstitutes Metagenomic Species Pan-genomes by binning co-abundant genes across metagenomic samples.

For further information, consult the paper published in Bioinformatics available at:

A binary for 64 bits Linux operating systems is freely available for non-commercial users after completing the form below. For any other use, please contact us.